A 1-Year, Open Label, Randomized Phase II Dose Finding Study of Degarelix for the Treatment of Prostate Cancer in North America-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A 1-Year, Open Label, Randomized Phase II Dose Finding Study of Degarelix for the Treatment of Prostate Cancer in North America

Published:2008-11 Issue:5 Volume:180 Page:1986-1992
ISSN:0022-5347
Container-title:Journal of Urology
language:en
Short-container-title:Journal of Urology

Author:

Gittelman Marc¹,Pommerville Peter J.²,Persson Bo-Eric³,Jensen Jens-Kristian⁴,Olesen Tine Kold⁴,

Affiliation:

1. Department of Urology, South Florida Medical Research, Aventura, Florida

2. Department of Urological Sciences, University of British Columbia, Victoria, British Columbia

3. Department of Global Marketing, Ferring Pharmaceuticals A/S, Copenhagen, Denmark

4. Clinical R&D, Ferring Pharmaceuticals A/S, Copenhagen, Denmark

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Reference21 articles.

1. Cancer statistics, 2007;Jemal;CA Cancer J Clin,2007

2. EAU guidelines on prostate cancer;Heidenreich;Eur Urol,2008

3. GnRH-receptor interaction;Nett;Biol Reprod,1981

4. Pituitary desensitization and the regulation of pituitary gonadotropin-releasing hormone (GnRH) receptors following chronic administration of a superactive GnRH analog and testosterone;Heber;Life Sci,1982

5. Gonadotropin-releasing hormone and its analogues;Conn;N Engl J Med,1991

Cited by 85 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Physiological and pharmacological overview of the gonadotropin releasing hormone;Biochemical Pharmacology;2023-06

2. An observational multicenter study to evaluate the efficacy and safety of degarelix® for prostate cancer in routine clinical practice;Cancer Urology;2022-08-14

3. Relugolix in the management of prostate cancer;Expert Review of Anticancer Therapy;2022-07-27

4. Hormone Treatment of Prostate Cancer:;Urologic Clinics of North America;2022-05

5. Advances with androgen deprivation therapy for prostate cancer;Expert Opinion on Pharmacotherapy;2022-02-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3